NCI Completes Long-Term Epidemiological Study on Breast and Ovarian Cancer, Laying the Foundation for PARP Inhibitor Development, Including AstraZeneca's Lynparza
Completion of Genomic Data and Market Impact in the Era of Precision Medicine
The National Cancer Institute (NCI) has completed its long-term epidemiological study (NCT00040222) on 377 patients with genetically high-risk breast cancer and ovarian cancer, along with their families, tracked over 24 years since 2002. This long-term project, combining germline mutation testing data with biospecimens from patients, has served as a cornerstone in elucidating the genetic mechanisms of cancer. In particular, it has provided direct genetic evidence for the development of targeted therapies, including Lynparza (olaparib), the first PARP inhibitor co-developed by AstraZeneca (AZN) and MSD (Merck & Co, MRK), transforming the paradigm of cancer drug development. NCI's long-term cohort construction has gone beyond simple data collection, serving as an infrastructure that dramatically reduces the cost of clinical trial design and target discovery for precision medicine drugs.
Securing Biobank Assets and the Value of Follow-up Translational Research
The research team secured high-quality biological samples, including DNA, serum, and tumor tissue, from participants to establish a biobank. This systematically accumulated genetic information from high-risk groups is essential material for discovering new tumor susceptibility genes and elucidating cancer mechanisms. By statistically demonstrating the correlation between gene mutations and actual cancer development, a clinical benchmark has been established, enabling global pharmaceutical companies to initiate follow-up translational research. This has led to a shorter development cycle for next-generation targeted therapies such as Talzenna (talazoparib) from Pfizer (PFE) and Zejula (niraparib) from GSK, providing patients with faster access to treatment.
Ensuring Data Reliability Through Adherence to Guidelines
This study strictly adhered to the guidelines of the American Society of Clinical Oncology (ASCO), and genetic mutation testing was performed only in laboratories with Clinical Laboratory Improvement Amendments (CLIA) certification, ensuring high-quality clinical testing. This guarantees the rigorous quality of the genetic data derived during the study, contributing to reducing the regulatory hurdles for the approval of companion diagnostics (CDx) in the future. By transparently sharing genetic cancer risk information with patients, the study proactively established ethical guidelines for clinical genetics. The high degree of data integrity can be used as a key benchmark by global regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) when evaluating the safety and efficacy of gene-based new drugs.
Expansion and Competitive Landscape of the Global PARP Inhibitor Market
The global PARP inhibitor market is currently valued at approximately $7.5 billion to $8.4 billion as of 2024 and is projected to grow to as much as $23.6 billion by 2035. AstraZeneca's Lynparza, which accounts for more than 38% of the market, recorded sales of $3.072 billion in 2024 alone, leading the market. With the successful completion of NCI's long-term study, the long-term tracking data of genetically high-risk groups, necessary for expanding indications and developing combination therapies for competing drugs such as Zejula and Talzenna, has been reinforced. This open access to high-quality data is expected to accelerate the pipeline development of new bioventures targeting new targets, diversifying competition in the market.
The completion of NCI's 24-year long-term epidemiological study is a significant milestone in accelerating new drug target discovery and supporting the long-term growth of the global PARP inhibitor market, which exceeds $7.5 billion as of 2024. With AstraZeneca's Lynparza recording annual sales of $3.072 billion and leading the market, the study provides essential BRCA1/2 mutation high-risk cohort data for designing expanded indication clinical trials for competing products such as GSK's Zejula and Pfizer's Talzenna. The CLIA-certified genomic and biobanking samples secured by researchers are utilized as key foundational research assets, from early-stage candidate discovery to late-stage Phase 3 trials and regulatory approval applications for safety profile validation. In the short term, it contributes to the refinement of early diagnosis and preventive treatment guidelines for hereditary breast and ovarian cancers, and in the medium to long term, it shortens the FDA approval process for companion diagnostics. Ultimately, the long-term tumor occurrence tracking data of high-risk 'Kindred' is expected to reduce investment risk in the fields of gene therapy and precision targeted anticancer drugs and significantly improve the productivity of translational research for biotech companies.
Source: ClinicalTrials.gov (api_ct)